No summary available.

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:30 p.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Tuesday, March 4, 2025. Jetzt den vollständigen Artikel lesen

Global investment firm Carlyle has agreed to acquire US medtech company Baxter International’s kidney care segment — to be named Vantive — for $3.8bn, concluding talks initially reported by Reuters and the Wall Street Journal last month.

Kirkland & Ellis is advising global investment firm Carlyle (NASDAQ: CG) on the $3.8 billion acquisition of global medtech company Baxter International Inc.s (NYSE:BAX) kidney care segment, which will be named Vantive. The transaction was announced on August 13, 2024. Under the terms of the definitive agreement, subject to certain closing adjustments, Baxter will receive […] The post Kirkland Advises Carlyle on $3.8 Billion Acquisition of Baxters Kidney Care Segment appeared first on Legal Desire Media and Insights .

Establishes Vantive as a leading standalone kidney care business backed by Carlyle’s global investment team and resources Sale follows robust process focused on maximizing stockholder value Provides increased flexibility to deploy capital toward opportunities to accelerate Baxter’s and Vantive’s respective growth objectives Represents key milestone in Baxter’s ongoing business transformation, enabling heightened strategic clarity, operational efficiency and innovation Baxter share…

Baxter International ($BAX) has agreed to sell its Kidney Care unit to private equity investment company, Carlyle Group ($CG) for $3.8 billion. The…

By Echo Wang NEW YORK (Reuters) - Buyout firm Carlyle Group struck a deal to acquire medical-device maker Baxter''s kidney-care unit Vantive for $3.8 b…

In a landmark move for the medtech industry, Carlyle Group (NASDAQ) has announced its decision to acquire Baxter International Inc.’s (NYSE) Kidney Care segment for a substantial $3.8 billion. This transaction will see the segment rebranded as Vantive and marks a significant shift in the global kidney care market. The acquisition, slated to close in […]

Baxter stock tumbled Tuesday after the medtech company agreed to sell its kidney segment to Carlyle for $3.8 billion.

On Tuesday, Baxter International Inc (NYSE: BAX ) agreed to sell its Kidney Care segment, Vantive, for $3.8 billion to The Carlyle Group Inc (NASDAQ: CG ) Baxter will receive approximately $3.5 billion in cash, with net after-tax proceeds currently estimated at approximately $3 billion . Baxter announced its intention to create a standalone kidney care company in January 2023 as part of its broader strategic realignment designed to enhance future performance and create value for all stakeholders. In March 2024, Baxter announced that it was in discussions to explore a potential sale … Full story available on Benzinga.com